Chapter1
AMR as a Systems Crisis
The Looming Crisis: Antimicrobial Resistance and Its Projected Global Impact Through 2050
Antimicrobial resistance (AMR), the ability of pathogens to withstand treatments once considered standard of care, is emerging as one of the most consequential global health and economic threats of the 21st century. It undermines the assumptions underpinning modern medicine: that infections tied to surgery, chemotherapy, intensive care, transplantation, and routine primary care can be reliably prevented or treated. What began as a technical concern about “resistant bugs” has become a macro-level crisis with implications for health systems, labor markets, national security, and globaldevelopment.
This chapter looks ahead from 2025 to 2050, using current evidence to trace the likely trajectory of AMR if left inadequately addressed. It summarizes projected mortality, economic damage, health-system disruption, and social consequences—and highlights the levers that can still bend thiscurve.
In this chapter, AMR is treated as asystems crisis: a threat that degrades reliability across interconnected functions—clinical decision-making, diagnostics, workforce capacity, ICU throughput, and hospital finances—producing cascading failures rather than isolated harms. The projections that follow are not destiny; they are conditional forecasts that can be improved through coordinatedaction.
2025–2030: Rapid Escalation and Early Shock
By the late 2020s, AMR is likely to be entrenched as a leading cause of death if current trajectories persist. A landmark analysis estimated 1.27 million deaths directly attributable to bacterial AMR in 2019, with 4.95 million deaths associated with infections complicated by resistance (Murray et al., 2022; GRAM Project, 2024). Multiple models suggest these numbers will rise steadily throughout the decade absent major improvements in stewardship, prevention, and access to effective therapies (Murray et al., 2022; GRAM Project, 2024). Misuse and overuse of antibiotics during the COVID-19 pandemic—especially in low- and middle-income countries (LMICs)—accelerated this trend. The pandemic saw empiric broad-spectrum antibiotic use across outpatient and inpatient settings, often without microbiologic confirmation, creating conditions conducive to the expansion of resistant strains (Mustafa et al., 2024).
Economic Cost and Healthcare Strain
The economic burden of AMR is already measurable and deepening. The World Bank (2017) warns that under high-resistance scenarios, AMR could generate global economic losses comparable to the 2008 financial crisis, cutting gross domestic product (GDP) by 1.1–3.8% annually in some countries by 2030 and producing $1–3 trillion in global GDP losses per year. The World Bank projects large increases in health-system costs under high-resistance scenarios, with additional annual costs reaching well into the hundreds of billions globally in ‘no additional action’ pathways (World Bank, 2017; Taylor et al., 2021).
At the hospital level, resistant infections increase case complexity, length of stay, and unit costs. In the United States alone, antibiotic-resistant infections cause more than 2.8 million infections and more than 35,000 deaths each year, generating at least $4.6 billion in direct health-care costs (CDC, 2019). These figures do not capture broader societal losses tied to reduced productivity, long-term disability, caregiver burden, and prematuremortality.
In LMICs, the same dynamic is far more destabilizing. Limited diagnostic capacity, constrained access to second- and third-line antibiotics, and high out-of-pocket spending often push households into long-term poverty due to resistant infections. Teillant et al. (2015) estimate that rising resistance can reduce effective antibiotic coverage for basic surgical and oncologic prophylaxis by more than 40% in some settings, driving preventable deaths and chronicdisability.
Health systems must also divert resources toward infection prevention and control (IPC), laboratory surveillance, and antimicrobial stewardship. These investments are necessary but draw personnel, funds, and attention away from other essential services. The result is visible strain: postponed elective procedures, full intensive care units (ICUs), staff attrition, and the systematic erosion of preventive and primary carecapacity.
Surge Fragility in the U.S. Hospital Grid
While AMR is expanding in complexity and scale, the United States’ hospital system—often presumed to be resilient—has become increasingly fragile. Decades of consolidation, workforce shortages, rural hospital closures, and declining margins have left vast regions of the country without the redundancy or surge capacity to withstand significant increases in critical illness. AMR is poised to strain this system differently than the COVID-19 pandemic because AMR is not seasonal, not self-limiting, and not subject to waves that eventually recede. It is a chronic, compoundingpressure.
As of 2025, nearly half of all U.S. rural hospitals operate at negative margins, and more than 430 are classified as vulnerable to closure (Chartis Center for Rural Health, 2025). Since 2010, approximately 180–200 rural hospitals have closed or converted to non-inpatient status, leaving entire multi-county regions—especially in the Deep South, Midwest, and Mountain West—without local acute-care capability (Chartis Center for Rural Health, 2024). These closures predate the peak of AMR’s projected surge but dramatically shrink the nation’s ability to absorb theconsequences.
The system’s fragility is not evenly distributed. It is patterned across geography, race, socioeconomic status, disability status, and population density. AMR will not strike a level playing field—it will strike a landscape already fractured by unequalaccess.
Rural Hospital Closures and Systemic Exposure
Rural hospitals serve populations with higher rates of chronic disease, less insurance coverage, higher social vulnerability, and greater distances to specialized care. They also disproportionately serve aging populations, which are most vulnerable to AMR-complicated infections. When such hospitals close, the effects are immediate and far-reaching:
